Fremanezumab▼ for Healthcare Professionals | Teva UK
For Healthcare Professionals:

Fremanezumab▼

Overview

▼ Medicines showing this symbol are subject to additional monitoring. This will allow quick identification of new safety information. The Summary of Product Characteristics, along with the Patient Information Leaflet for Fremanezumab from Teva can be downloaded below, along with other information such as Frequently Asked Questions where applicable. To contact Teva's Medical Information Service email: medinfo@tevauk.com or telephone: 0207 540 7117.

Available as
  • Pre-filled Pen for Injection
  • Pre-filled Syringe for Injection

Date of preparation: April 2023
D: COB-GB-NP-00112 (V1.0) / T: COB-GB-NP-00102 (V1.0) / M: COB-GB-NP-00103 (V1.0)

Date of preparation: April 2023
D: COB-GB-00016 (V1.0) / T: COB-GB-00014 (V1.0) / M: COB-GB-00015 (V1.0)

Date of preparation: April 2023
D: COB-GB-NP-00104 (V1.0) / T: COB-GB-NP-00105 (V1.0) / M: COB-GB-NP-00106 (V1.0)